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Abstract
Background: The purpose of this study was to validate the accuracy of an alternative cervical
cancer test – visual inspection with acetic acid (VIA) – by addressing possible imperfections in the
gold standard through latent class analysis (LCA). The data were originally collected at peri-urban
health clinics in Zimbabwe.
Methods:  Conventional accuracy (sensitivity/specificity) estimates for VIA and two other
screening tests using colposcopy/biopsy as the reference standard were compared to LCA
estimates based on results from all four tests. For conventional analysis, negative colposcopy was
accepted as a negative outcome when biopsy was not available as the reference standard. With
LCA, local dependencies between tests were handled through adding direct effect parameters or
additional latent classes to the model.
Results: Two models yielded good fit to the data, a 2-class model with two adjustments and a 3-
class model with one adjustment. The definition of latent disease associated with the latter was
more stringent, backed by three of the four tests. Under that model, sensitivity for VIA
(abnormal+) was 0.74 compared to 0.78 with conventional analyses. Specificity was 0.639 versus
0.568, respectively. By contrast, the LCA-derived sensitivity for colposcopy/biopsy was 0.63.
Conclusion: VIA sensitivity and specificity with the 3-class LCA model were within the range of
published data and relatively consistent with conventional analyses, thus validating the original
assessment of test accuracy. LCA probably yielded more likely estimates of the true accuracy than
did conventional analysis with in-country colposcopy/biopsy as the reference standard. Colpscopy
with biopsy can be problematic as a study reference standard and LCA offers the possibility of
obtaining estimates adjusted for referent imperfections.
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Background
Cervical cancer, the second most commonly diagnosed
cancer among women worldwide, can be a preventable
disease. Although the Pap smear remains the most com-
mon screening test for cervical cancer, many less devel-
oped countries do not have adequate resources to
implement cytology-based prevention programs. An alter-
native, low-cost test, visual inspection using acetic acid
(VIA), has emerged for use in low-resource settings where
it can be performed by auxiliary health professionals [1-
3]. VIA is similar to colposcopy in that acetic acid is
applied and any acetowhite lesion is visualized, although
with VIA there is no magnification.
VIA accuracy studies have yielded a range of sensitivity
and specificity values spanning from approximately 60
percent to over 90 percent [4-14]. While this range is nar-
rower than observed for other tests including cytology
(23% to 99% for sensitivity and 7% to 97% for specifi-
city), it is important to investigate possible reasons for
inter-study variability [15]. Some have questioned
whether the variability of results across studies is due, at
least in part, to imperfections with the reference standard
used. For cervical cancer, the "gold" standard for estab-
lishing a diagnosis is biopsy [16]. The VIA studies cited
above have involved a variety of reference standard meas-
ures. These include: 100 percent biopsy sampling, a com-
bined colposcopy/biopsy reference standard for all
participants, biopsy for colposcopically-suspicious lesions
only, and colposcopy with histology only for women test-
positive on all screening tests [i.e., visual inspection, Pap,
human papilloma virus (HPV) and cervicography] [4-
6,8,10,12-14]. Even among studies with similar reference
standard measures, another source of variability across
studies could be differences in the quality of the reference
standard. Subjective (human) error may have affected the
quality of colposcopy or the quality of tissue collection,
slide fixing and biopsy interpretation which could have
led to misclassification of the reference standard [17,18].
Most published studies on VIA involve use of conven-
tional methods and a 2 × 2 table for assessing test accuracy
(i.e., sensitivity and specificity). In recent years, several
statistical methods have been used to evaluate new tests
when no or an imperfect gold/reference standard is avail-
able [19-21]. LCA is a statistical technique, originally
developed in the early 1950s, that allows for the accuracy
of a new test to be assessed in the absence of a gold stand-
ard. It does this by using the statistical associations among
various tests performed on the same individual to define
unobserved (latent) disease. The likelihood of the rela-
tionship between latent disease, the new test under inves-
tigation and the other tests is then maximized to yield
sensitivity and specificity estimates [22]. Historically, LCA
has been used in biomedical applications to identify dis-
ease based on observable traits [23-25]. More recently,
there has been increased interest in using LCA to evaluate
diagnostic or screening tests [26-30].
The objectives of this analysis were two-fold: 1) to assess
test accuracy using LCA assuming no gold standard and to
compare those values with conventional estimates to
explore the effect of any gold standard imperfections in
calculating the latter; 2) to assess whether the assumption
of independence between VIA and coloposcopy as a com-
ponent of the gold standard reference test were met (a pre-
requisite for valid test accuracy assessment). The second
objective corresponds to issues that have been raised
regarding the appropriateness of using colposcopy as a
reference standard for VIA accuracy studies as the two tests
are similar in nature, both involving visual observation of
the cervix after acetic acid wash [31].
Methods
The dataset used in this exercise is a subset of data from a
previously published, cross-sectional study [5]. All sub-
jects participating in that study gave informed consent
and the study was approved by the Institutional Review
Board at Johns Hopkins Bayview Medical Center, Balti-
more, USA.
The original study involved 2203 women, aged 25 to 55
years, who attended 15 primary-care clinics in two peri-
urban areas near Harare, Zimbabwe between October
1996 and August 1997. Details of the original study
design, data collection and biological sample collection
procedures are available elsewhere [5]. All women
enrolled in the study were offered and scheduled to
receive four tests: VIA, a Pap smear, colposcopy with
biospy (the latter when clinically indicated only) and a
HPV DNA test [Hybrid Capture II (HC2), (Digene Corpo-
ration, Gaithersburg, USA].
Specially-trained nurse-midwives performed VIA using a 4
percent acetic acid dilution. A cytological specimen from
the same woman was independently assessed by a local
cytopathologist (and later reviewed by a board-certified,
cytopathologist at the Johns Hopkins Bayview Medical
Center, Baltimore, USA). In addition, HPV testing was
independently performed for all women (at Johns Hop-
kins University, Bloomberg School of Public Health, Bal-
timore, USA) using the B probe of HC2 targeting 13 high-
risk HPV types [32]. A colposcopic examination was per-
formed by one of two local faculty gynecologists, blinded
to all other test results, shortly after VIA testing and the
cytology/HPV samples had been obtained. Almost all (97
percent) women received colposcopy. Biopsy was per-
formed only for cases suspicious on colposcopy (n = 595).BMC Medical Research Methodology 2007, 7:36 http://www.biomedcentral.com/1471-2288/7/36
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In this study, analysis were performed on the subset of
women (n = 2073) for whom all four test results (VIA, Pap,
HPV and colposcopy/biopsy, here considered as one com-
bined test) were available. A combined reference standard
was developed incorporating biopsy results when availa-
ble; negative colposcopy was accepted as a negative out-
come when no biopsy was taken. Such a combined
reference standard has been considered appropriate for
cervical cancer test accuracy studies given ethical and
other issues involved in performing biopsy for test-nega-
tives [13]. The availability of colposcopy and/or biopsy
results to form a combined reference standard for 97 per-
cent of all study participants meant that conventional esti-
mates of sensitivity/specificity could be calculated with an
ignorable risk for verification bias. All tests were catego-
rized into two levels for sensitivity/specificity estimates.
Cervical intraepithelial neoplasia grade 2 or worse
(CIN2+) on biopsy or high grade squamous intraepithe-
lial lesion or worse (HGSIL+) on colposcopy was used as
the cutoff point defining disease in all analyses. This
threshold of disease was chosen since this is the severity
level usually treated in Zimbabwe.
In the present analysis, LCA (as implemented in Latent
Gold Version 3.0 software) was applied to four "manifest"
variables (VIA, Pap smear, HC2, and colposcopy/biopsy)
to construct a "latent" variable that could serve as a meas-
ure of the reference standard defining true disease [33].
Since LCA estimates the conditional probability of a given
latent class (e.g., presence or absence of high grade lesions
or worse) for each level of the observed variables, sensitiv-
ity and specificity in relation to the latent disease variable
could be calculated. Using LCA, maximum-likelihood-
based estimates of the standard errors of the various prob-
ability estimates were also calculated to derive confidence
intervals. We then compared LCA-estimated sensitivity
and specificity estimates to those conventionally derived
from 2 × 2 tables with binomial standard errors (for VIA,
Pap, and HC2 against colposcopy/biopsy as the reference
standard).
A fundamental assumption of LCA is that the manifest
variables are locally independent. That is, within (or local
to) a given latent class, the manifest variables should be
statistically unrelated to or independent from each other.
Bivariate residuals, which reflect any remaining associa-
tion among each pairing of manifest variables after esti-
mation of the latent classes, indicate whether this
assumption was in fact met.
Vermunt and Magidson suggest that residuals above 1.0
indicate possible local dependencies which can be
adjusted for in LCA models through the introduction of
"direct effects", representing the excess variation between
two variables. Adding a direct effect increases the log-like-
lihood (LL) of the model, indicating better fit of the data
to the model. The bivariate residual value approximates
the increase in LL observed with the addition of the direct
effect variable [33]. The software we used supports adjust-
ment for local dependencies through the introduction of
direct effects [34-36].
Model fit is also indexed by the likelihood ratio chi-square
(L2) which decreases as the fit of the model improves. A sig-
nificant p-value associated with the L2 indicates that the
manifest variables (here, the different tests) have associa-
tions with each other that are not accounted for by the
model. LCA modeling continues with the addition of
latent classes and/or adjustment for local dependencies
until adequate fit is reached, as indicated by a non-signif-
icant p-value.
For our LCA, the tests were first categorized into three lev-
els (Table 1) to increase the amount of information avail-
able to calculate the latent classes. Then, the tests were
categorized dichotomously (as with the conventional test
accuracy formula) to calculate sensitivity/specificity val-
ues as follows: VIA negative (normal, atypical/inflamma-
tion) versus VIA positive (abnormal, cancer); Pap negative
[normal, inflammation, atypical squamous cells of uncer-
tain significance (ASCUS), atypical glandular cells of
uncertain significance (AGUS)] versus Pap positive [low
grade squamous intraepithelial lesions (LGSIL), HGSIL,
cancer]; HPV negative [< 1.0 relative light units (RLU)
compared to control] versus HPV positive (> = 1 RLU
compared to control); colposcopy/biopsy negative (nor-
mal, inflammation, pure HPV, LGSIL) versus colposcopy/
biopsy positive (HGSIL, cancer). In this analysis, however,
the latent class-derived reference standard was used as the
measure of "true" disease. A preliminary 1-class model
Table 1: Trichotomous coding scheme for the four tests
Test Low Medium High
VIA Normal Atypical Abnormal, Cancer
Pap Normal, Inflammation, Ascus, Agus LGSIL HGSIL, Cancer
HPV < 1.0 RLU compared to control >= 1.0 RLU and < 20.0 RLU compared to control >= 20.0 RLU compared to control
Colposcopy/Biopsy* Normal, Inflammation, Pure HPV LGSIL HGSIL, Cancer
* For subjects with both biopsy and colposcopy results, biopsy result was used.BMC Medical Research Methodology 2007, 7:36 http://www.biomedcentral.com/1471-2288/7/36
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provided a baseline measure of the amount of association
among the tests, as indicated by the log-likelihood (LL).
Other LCA models were then generated to explain these
associations and successively evaluated for their fit to the
data.
With latent class modeling, it is often possible to produce
several different models that adequately fit the data. In the
present exercise, two such models were generated: one
with two latent classes and one with three. There is no sin-
gle statistical tool that can definitively support the selec-
tion of one model over the other and, therefore, final
model selection must be based on knowledge of the bio-
logical processes under study, as well as the particular
characteristics of the study sample. However, information
criterion statistics such as the Akaike Information Crite-
rion (AIC), available in Latent Gold Version 3.0, have
been developed to provide an idea of the relative distance
of two or more models from a theoretical best model [37].
The AIC is a function of the LL and the number of param-
eters (K) in the model: AIC = -2(LL) + 2K [38]. Given two
or more fitted models on the same dataset, the one with
the lower AIC value is considered better. From the equa-
tion for AIC, it is apparent that as LL increases, AIC
decreases (gets better). Additionally, as the number of
parameters (K) in a model increases, the AIC increases
(gets worse). Thus, the AIC favors a more parsimonious
model (lower K), all other things being equal.
Results
Table 2 gives overall statistics for the final two best-fit LCA
models (2-class and 3-class). As noted, while the simple 2-
class model accounted for a large proportion of the vari-
ance, there still remained a significant amount of variance
to be explained, as evidenced by the significant p value
(4.5*10-9). Examination of the model bivariate residuals
(= 10.03) revealed a local dependency between VIA and
colposcopy/biopsy, indicating that significant association
remained between these two variables after construction
of the two latent classes (Table 3 provides the bivariate
residuals for all models tested). A 2-class model with one
adjustment for the residual association between VIA and
colposcopy/biopsy was subsequently developed and
results for this also appear in Table 2.
Although this adjustment accounted for more variance (as
seen by the increase in LL and decrease in L2), the overall
model p value was still statistically significant from the 1-
class, saturated model (p = 0.016), indicating more vari-
ance still needed to be explained. The 2-class model with
one adjustment had a residual score of 2.4568 for the
association of Pap smears with colposcopy/biopsy, mean-
ing that these two tests were also locally dependent. Add-
ing a second adjustment for this local dependency
resulted in a non-significant p-value (0.12), indicating a
good fit of the 2-class, two adjustment model to the data.
Figure 1 shows the conditional probabilities of different
test results for the 2-class model constructed from all four
tests (with trichotomous categories) with two local
dependency adjustments.
The last row of Table 2 gives statistics for another LCA
model which was alternatively developed to address the
residual score for the local dependency between the Pap
test and colposcopy/biopsy. Rather than adding another
direct effect for this second local dependency, a 3-class
model was generated maintaining the single direct effect
Probability of the Two Class LCA Model Test Result Condi- tional on the Latent Class* Figure 1
Probability of the Two Class LCA Model Test Result Condi-
tional on the Latent Class*. *model probabilities generated 
from trichotomous results for all four tests.
0.273 (0.012)
0.428 (0.014)
0.299 (0.013)
0.997 (0.004)
0.003 (0.003)
0.807 (0.030)
0.857 (0.010)
0.001 (0.001)
0.158 (0.011)
0.035 (0.031)
0.114 (0.009)
0.030 (0.005)
0.111 (0.018)
0.252 (0.025)
0.637 (0.034)
0.583 (0.040)
0.084 (0.017)
0.251 (0.026)
0.558 (0.031)
0.889 (0.025)
0.191 (0.018)
0.027 (0.017)
0.115 (0.016)
0.302 (0.031)
0 0.2 0.4 0.6 0.8 1 1.2
VIA normal
VIA inflamed
VIA abnormal/ca
Pap normal/ascus
Pap LGSIL
Pap HGSIL+
HPV normal (<1)
HPV 1-19
HPV 20+
Colp/biop normal
Colp/biop LGSIL
Colp/biop HGSIL+
Prob(test result) given class; standard error in parenthesis
Class 1 (p=0.698) Class 2 (p=0.302)
Table 2: Comparative statistics for various LCA models involving 
all four tests
Model Parameters LL L2 pA I C
1-class 8 -6592.39 1121.16 5.70E-188 13200.77
2-class 17 -6106.87 150.13 4.50E-09 12247.74
2-class with 
one 
adjustment
21 -6074.14 84.67 0.016 12190.28
2-class with 
two 
adjustments
25 -6065.57 67.54 0.12 12181.15
3-class with 
one 
adjustment
30 -6059.23 54.86 0.3 12178.47BMC Medical Research Methodology 2007, 7:36 http://www.biomedcentral.com/1471-2288/7/36
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for the dependency between VIA and colposcopy/biopsy.
Figure 2 presents the conditional probabilities of the vari-
ous test results given each class for this model. Note that
this 3-class model with just one adjustment accounts for
slightly more variance than did the 2-class model with
two adjustments, having a higher likelihood (LL).
Although the fit of this model to the data using LL appears
slightly better than the 2-class model with two adjust-
ments, the difference in the AIC statistics (12178.47 ver-
sus 12181.15) is very small (2.68), suggesting that the two
models are similarly distant from a theoretical best
model. That is, both models could be considered accepta-
ble by the AIC criterion. Their relative usefulness, there-
fore, also needed to be evaluated in terms of biological
plausibility (see Discussion).
As described earlier, sensitivity and specificity under the
two models were calculated by recoding each test into its
standard dichotomous categories. This was done by com-
bining the appropriate conditional probabilities from Fig-
ures 1 and 2. For example, in the 3-class model, the
sensitivity of VIA was 0.74 (probability of VIA = abnormal
or cancer, given class 3). Specificity was 0.57. In that
model, class 1 (p = 0.682) and class 2 (p = 0.200) com-
bine to form non-disease. Specificity was calculated as
0.323 (probability of VIA inflammation given class 2)
plus 0.117 (probability of VIA normal given class 2) mul-
tiplied by the probability of class 2 (0.200), plus the anal-
ogous values for Class 1, i.e., 0.429 (probability of VIA
inflammation given class 1) plus 0.276 (probability of
VIA normal given class 1) multiplied by the probability of
class 1 (0.682).
Table 4 provides a summary of the prevalence and sensi-
tivity and specificity values for all tests, for comparative
purposes, for both the 2-class and 3-class LCA models.
The first two rows are the conventionally-derived esti-
mates of sensitivity and specificity for the three tests (for
comparative purposes, with disease defined at two thresh-
olds: HGSIL+ and LGSIL+). The last two rows represent
the estimates for all tests from the two LCA models. The
definition of positive for each test in the model is pro-
vided in the third column.
Discussion
There are various aspects of study design and implemen-
tation that can affect the validity of test accuracy studies
[39]. Regarding the accuracy of VIA as a test for (pre)can-
cer of the cervix, the majority of published studies to date
have been conducted in low-resource settings. Differences
in the threshold point defining VIA test positive, the
threshold defining disease (LGSIL, HGSIL or cancer), the
intensity and timing of provider training, the background
experience and qualifications of the providers, sample
sizes and sexually-transmitted disease risk of the partici-
pating women, among other factors, all could potentially
account for differences in observed VIA accuracy estimates
[40,41].
Two problems in particular – the sometimes variable
quality of gold/reference standard tests and verification
bias – have the potential to substantially negatively affect
test accuracy results [42-44]. This analysis focused on clar-
ifying the potential problem of imperfections in the gold/
reference standard. It also addressed another purported
issue with VIA accuracy studies, that is, the potential lack
of independence between VIA and coloposcopy when the
latter is used as, or part of, the reference standard.
In our opinion, the latent class model with three classes
represents a more realistic assessment of the true sensitiv-
ities/specificities of VIA, Pap smear, and HC2 testing than
do results from the conventional model with colposcopy/
biopsy as the reference standard. This model showed good
fit to the data and likely yields a more accurate study ref-
erence standard. The 3-class model offers a more stringent
definition of disease, backed by three of the four tests (not
the Pap test) and a prevalence rate of disease (CIN2+/
Probability of the Three Class LCA Model Test Result Con- ditional on the Latent Class* Figure 2
Probability of the Three Class LCA Model Test Result Con-
ditional on the Latent Class*. *model probabilities generated 
from trichotomous results for all four tests.
0.276 (0.013) 
0.429 (0.014) 
1.000 (0.001) 
0.819 (0.032) 
0.856 (0.010) 
0.295 (0.013) 
0.000 (0.001) 
0.000 (0.001) 
0.031 (0.005) 
0.113 (0.009) 
0.032 (0.031) 
0.149 (0.012) 
0.117 (0.034) 
0.323 (0.036) 
0.560 (0.046) 
0.691 (0.050) 
0.004 (0.020) 
0.144 (0.033) 
0.244 (0.041) 
0.065 (0.017) 
0.047 (0.022) 
0.125 (0.053) 
0.808 (0.040) 
0.872 (0.058) 
0.152 (0.029) 
0.744 (0.049) 
0.440 (0.042) 
0.374 (0.036) 
0.186 (0.031) 
0.028 (0.016) 
0.041 (0.020) 
0.931 (0.025) 
0.074 (0.110) 
0.294 (0.068) 
0.632 (0.112) 
0.104 (0.040) 
0 0.2 0.4 0.6 0.8 1 1.2
VIA normal 
VIA inflamed 
VIA abnormal/ca 
Pap normal/ascus 
Pap LGSIL 
Pap HGSIL+ 
HPV normal (<1) 
HPV 1-19 
HPV 20+ 
Colp/biop normal 
Colp/biop LGSIL 
Colp/biop HGSIL+ 
Prob(test result) given class; standard error in parenthesis
Class 1 (p=0.682) Class 2 (p=0.200) Class 3 (p=0.118)BMC Medical Research Methodology 2007, 7:36 http://www.biomedcentral.com/1471-2288/7/36
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HGSIL+ or cancer) for class three more consistent with
that calculated using colposcopy/biopsy as the reference
standard (around 10 percent). Prevalence values for the
three latent classes in this model were 0.682 (SE = 0.029),
0.200 (SE = 0.035) and 0.118 (SE = 0.022) for latent dis-
ease class one, two, and three, respectively (Table 4).
Given the high probabilities with more severe VIA, HC2,
and colposcopy/biopsy results, class three in the 3-class
model can more likely be interpreted as true "disease"
(CIN2+/HGSIL+). This is supported by the high sensitivity
rates for all tests in this class, as well as similar probability
profiles for VIA and colposcopy/plus the high HC2 RLU
levels (suggestive of high viral loads).
With this subset of Zimbabwe data, the LCA-derived sen-
sitivity and specificity for VIA were fairly consistent with
conventionally-derived estimates as well as the range of
published values [4-13]. For comparative purposes, the
LCA-derived sensitivity of HC2 was close to 97 percent for
both the 3- and 2-class models. This is considerably
higher than the conventionally derived estimate (0.80)
and is more consistent with the ranges cited in some
industrialized country meta-analyses [45]. However,
other reviews indicate a slightly wider variation in HC2
sensitivity and reports from developing countries show a
sensitivity lower than that commonly reported for devel-
oped countries [32,46-49]. In the recent scientific litera-
ture, the sensitivity of cytology at cutoff LGSIL+ for an
outcome of CIN2+ ranged from 23% to 99% and the spe-
cificity from 7 to 97% [15]. Our LCA-derived cytology sen-
sitivity and specificity differed slightly from the
conventionally-derived values and fell within these pub-
lished value ranges.
In this analysis, HC2 sensitivity showed the greatest
change (gain) among the three tests comparing the con-
ventional results to those using the latent reference stand-
ard with class three defining disease. Specificity for HC2,
on the other hand, was relatively low for the 3-class
model. Only the Pap test in this model continued to per-
form "counter-intuitively", with higher probabilities of
latent disease class three for less severe Pap test results.
However, this finding is consistent with the results from
the initial, conventionally-derived cytology analysis that
indicated a low ability for Pap smears in this setting to
identify true disease [5].
Given the conditions of the Zimbabwe study, where the
colposcopist was blinded to the results of any other test
result, our LCA findings may reflect the more subjective
nature of colposcopy and the consequences of a colpo-
scopist seeing what they think is an insignificant lesion,
for which they elect not to take a biopsy. The latent class
model, which takes into account the additional informa-
tion provided by the HC2, VIA and Pap results, classifies
as true disease some lesions assessed on coloposcopy as
"insignificant", rendering those colposcopy/biopsy results
"false negatives". These translate into a reduced LCA-
derived sensitivity value for the colposcopy/biopsy com-
bined test.
Although the subjective nature of colposcopy has been
commented on by many authors, the data from this exer-
cise demonstrate the degree to which such subjectivity can
potentially affect sensitivity or specificity estimates when
a test is being evaluated with colposcopy/biopsy as a com-
bined reference standard [50-52]. Mitchell et al (1998)
summarized the sensitivity and specificity of colposcopy
(compared to biopsy as the reference standard) through a
meta-analysis of 9 studies [16]. They found a range of sen-
sitivities from 0.30 – 0.99 and a range of specificities from
0.39 – 0.93, with a weighted mean sensitivity and specifi-
city of 0.85 and 0.69, respectively. All this suggests that
colposcopy may have limitations when used as a "refer-
ence" standard, alone or in combination with biopsy, for
cervical cancer test accuracy studies.
In this study, despite apparent imperfections in the refer-
ence standard, the conventionally-derived VIA results fell
within the range of published data and were relatively
Table 3: Bivariate residuals for various LCA models
1-class (baseline) 2-class 2-class with 
adjustment for VIA * 
Colpo/Biop1
2-class with additional 
adjustment for Pap * 
Colpo/Biop
3-class with 
adjustment for VIA * 
Colpo/Biop
VIA * Pap 25.734 0.778 0.419 0.661 0.823
VIA * Colpo/Biop 46.100 10.027 0.000 0.000 0.000
VIA * HPV 42.092 0.549 0.775 0.299 0.267
Pap * Colpo/Biop 61.058 1.848 2.457 0.000 0.597
Pap * HPV 126.607 0.772 0.507 0.455 0.198
Colp/Biop * HPV 63.347 1.136 1.111 1.163 0.446
1 Colpo/Biop = colposcopy/biopsyBMC Medical Research Methodology 2007, 7:36 http://www.biomedcentral.com/1471-2288/7/36
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consistent between with the 3-class LCA model (0.775
versus 0.744, respectively, for sensitivity and 0.639 and
0.568, respectively for specificity). HC2 in this study how-
ever proved to have higher sensitivity when measured
using LCA. This may explain, in part, the discrepancy
observed between study results from industrialized coun-
tries versus those originally from Zimbabwe [32]. How-
ever, as noted earlier, lower HC2 sensitivity has also been
observed in other developing country studies [47-49].
This could similarly be due to inadequacies in the gold
standard used or to imperfections in sample collection,
transport or processing or a combination.
The age range of the women (22–55) was limited in this
study for two important reasons. First, because large num-
bers of women can be infected with HPV but not have per-
sistent disease, we wanted to maximize chances that any
identified lesions would likely represent real disease ver-
sus squamous metaplasia, inflammation or transient
infection with HPV. Second, as women age, especially
when they become post-menopausal, the squamo-colum-
nar junction (which is used as an anatomical landmark
for VIA assessments) recedes into the cervical canal and
sometimes cannot be visualized. In such women, VIA is
likely to be incomplete or unsatisfactory affecting the
accuracy of the test. This study criterion limits the general-
izablity of the results to the population of women of the
same age range. However, for developing countries seek-
ing more affordable cancer prevention strategies, given
the natural history of disease and the intrinsic limitations
of VIA among older women, it has been shown that focus-
ing on this age range is cost effective [53].
Conclusion
To have greater confidence in results of conventional
accuracy studies for existing or proposed cervical cancer
screening tests, especially where there are questions about
the reference standard, analyses involving LCA merit more
attention. In this particular setting, LCA yielded accuracy
estimates which, after adjustment, fell within the range of
values observed in studies where high quality colposcopy
and biopsy were used [45,46]. Additionally, using LCA it
was possible to account for any correlation between VIA
and colposcopy which both rely on visual interpretation
Table 4: Comparative values: conventional versus LCA model results
Reference standard Disease 
prevalence
 (± SE)
Test positive Sensitivity (± SE) (*) Specificity (± SE)
1. Colposcopy/Biopsy LGSIL+ 0.233
(0.009)
VIA Abnormal, CA 0.640 (0.022) 0.671 (0.012)
Pap LGSIL + 0.298 (0.021) 0.923 (0.007)
HPV >= 1.0 RLU 0.649 (0.022) 0.638 (0.012)
2. Colposcopy/Biopsy HGSIL+ 0.096
(0.006)
VIA Abnormal, CA 0.775 (0.030) 0.639 (0.011)
Pap LGSIL + 0.445 (0.035) 0.905 (0.007)
HPV >= 1.0 RLU 0.800 (0.028) 0.613 (0.011)
3. LCA disease derived from 
Trichotomous (†) VIA, Pap, HPV, 
including colposcopy/biopsy: 2 class 
solution
0.302
(0.028)
VIA Abnormal, CA 0.637 0.701
Pap LGSIL + 0.417 0.997
HPV >= 1.0 RLU 0.973 0.807
Colposcopy/Biopsy LGSIL+ (‡) 0.442 0.857
Colposcopy/Biopsy HGSIL+ 0.251 0.970
4. LCA disease derived from 
Trichotomous (†) VIA, Pap, HPV, 
including colposcopy/biopsy: 3 class 
solution
0.118 (§)
(0.022)
VIA Abnormal, CA 0.744 0.568
Pap LGSIL+ 0.560 0.820
HPV >= 1.0 RLU 0.972 0.568
Colposcopy/Biopsy LGSIL+ 0.926 0.758
Colposcopy/Biopsy HGSIL+ 0.632 0.860
(*) Standard errors (SE) are not given for the LCA-derived sensitivity and specificity estimates because some of these estimates are themselves 
calculated from combinations of conditional probabilities, which have individual maximum-likelihood estimated (MLE) standard errors. The MLE 
standard errors for these component conditional probabilities are given in Figures 1 and 2, in parentheses.
(†) Trichotomous response codes are used to define the latent classes, but results are re-interpreted dichotomously in order to calculate sensitivity 
and specificity estimates.
(‡) Results are given for Colposcopy/Biopsy with a low threshold (LGSIL+ is test positive, as it would be for Pap smears), and also with a high 
threshold (HGSIL+) as the latter is the threshold at which the gold standard for VIA testing is usually set when using the traditional formula.
(§) Prevalence of class 3 (disease) in a 3-class model; all other LCA prevalence estimates are from 2-class models.BMC Medical Research Methodology 2007, 7:36 http://www.biomedcentral.com/1471-2288/7/36
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of the cervix after acetic acid application. If not adjusted
for, this dependency between the test and the gold stand-
ard artificially inflates sensitivity [31].
LCA however also has its limitations as a "diamond"
standard is ultimately required to verify the LCA truth
[54]. Under this approach, disease is not formally defined
but rather latent disease (truth) is a mathematically
defined entity that does not necessarily correspond with a
clinically relevant status. Moreover, LCA modeling
requires specification of the joint distribution of test
results, conditional on disease status. The model however
cannot be fully tested with the observed data. Statistical
associations between tests therefore should be under-
stood biologically otherwise the meaning of the resulting
estimates may be unclear [22]. Consequently, researchers
designing screening/diagnostic test studies should desig-
nate resources for verifying true disease outcome using an
improved gold standard on at least a representative subset
of study subjects [55]. Consideration can also be given to
alternative approaches to evaluating diagnostic/screening
test accuracy (e.g., a composite reference standard) when
a gold standard does not exist [56,57].
Additionally, given that a perfect reference standard for
cervical cancer may be unattainable, even in a controlled
clinical setting, efforts to determine the relative usefulness
of new tests should also consider how consistent study
results are with the weight of existing data rather than try-
ing to identify a single, best "truth". In this regard, a recent
cost-effectiveness analysis of cervical cancer screening
strategies showed that (under model assumptions, includ-
ing industrialized country accuracy values for HC2) VIA,
with immediate treatment for test-positive women at first
visit, was similarly effective in reducing cancer incidence
over the lifetime of the simulated cohort as HC2 screening
with treatment at a second followup visit (26 percent ver-
sus 27 percent cancer incidence reduction, respectively).
The HC2-based approach was less cost-effective, however,
than VIA with the immediate option of treatment – the
main factor being the number of women in resource-lim-
ited environments who often drop out when more than
one visit linking testing and treatment is involved. Cytol-
ogy, followed by treatment of test-positive women at a
second visit, was the least effective (19 percent cancer inci-
dence reduction) and the least cost-effective [53].
In 1994, the World Health Organization recommended
exploring the benefits of VIA as an alternative screening
test for cervical cancer in underserved developing coun-
tries [58]. This study confirms the accuracy of VIA in
detecting lesions requiring treatment at the hands of
nurse-midwives in such a low resource setting. This find-
ing, plus the fact that VIA is simple to administer, can be
performed by nurse-midwives and the results are immedi-
ately available, make it a particularly valuable option for
many resource-poor settings.
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